bioMerieux' HIV viral load assay gains US nod:
This article was originally published in Clinica
The US FDA has approved for sale the bioMerieux HIV-1 quantitative viral load assay designed to aid in prognosis and therapeutic monitoring. The NucliSens HIV-1 QT assay uses the company's proprietary nucleic acid sequence-based amplification technology to identify the levels of HIV-1 viral RNA in plasma. The test can be used to monitor the effects of anti-retroviral therapy, says the company, a division of France's bioMerieux-Pierre Fabre Group.